Literature DB >> 31310175

LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.

Sang Min Lee1, Jeong Min Lee1, Su Joa Ahn1, Hyo-Jin Kang1, Hyun Kyung Yang1, Jeong Hee Yoon1.   

Abstract

Background Few studies have reported on the diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) LR-5 or LR-5 V in the diagnosis of hepatocellular carcinoma (HCC) using MRI with gadoxetate disodium. Purpose To determine the diagnostic performance of LI-RADS version 2018 (hereafter, v2018) on gadoxetate disodium-enhanced MRI in comparison with LI-RADS version 2017 (hereafter, v2017) for the diagnosis of HCC in patients with cirrhosis or chronic hepatitis B viral infection or at high risk for HCC. Materials and Methods This retrospective study between January 2013 and October 2015 evaluated consecutive patients at high risk for HCC who had at least one observation of 10 mm or greater on gadoxetate disodium-enhanced MRI and no history of previous treatment for hepatic lesions. MRI features were reviewed by three radiologists. Observations were categorized according to LI-RADS v2018 and LI-RADS v2017. Per-observation sensitivity and specificity of LR-5 using LI-RADS v2017 and v2018 were compared using generalized estimating equation models. Results A total of 422 observations, including 234 HCCs confirmed by results of pathologic examination in 387 patients (305 men and 82 women; mean age ± standard deviation, 59 years ± 10), were included. In all observations, LI-RADS v2018 provided higher sensitivity than LI-RADS v2017 (81% [189 of 234] vs 68% [160 of 234], respectively; P < .001). In small observations (10-19 mm), LI-RADS v2018 yielded much higher sensitivity than LI-RADS v2017 (76% [34 of 45] vs 11% [five of 45], respectively; P < .001) with relatively little impairment of specificity (94% [121 of 128] vs 99% [127 of 128], respectively; P = .013). Conclusion Updated LR-5 criteria of Liver Imaging Reporting and Data System (LI-RADS) version 2018 on gadoxetate disodium-enhanced MRI can improve sensitivity in the diagnosis of small hepatocellular carcinomas (10-19 mm) with only slight impairment in specificity compared with the criteria of LI-RADS version 2017. © RSNA, 2019 Online supplemental material is available for this article.

Entities:  

Year:  2019        PMID: 31310175     DOI: 10.1148/radiol.2019182867

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  18 in total

1.  Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.

Authors:  Jingbiao Chen; Sichi Kuang; Yao Zhang; Wenjie Tang; Sidong Xie; Linqi Zhang; Dailin Rong; Bingjun He; Ying Deng; Yuanqiang Xiao; Wenqi Shi; Kathryn Fowler; Jin Wang; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2020-10-11

Review 2.  LI-RADS and transplantation: challenges and controversies.

Authors:  Guilherme M Cunha; Dorathy E Tamayo-Murillo; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2021-01

3.  Imaging of hepatocellular carcinoma: a pilot international survey.

Authors:  An Tang; Karma Abukasm; Guilherme Moura Cunha; Bin Song; Jin Wang; Mathilde Wagner; Christoph F Dietrich; Giuseppe Brancatelli; Kazuhiko Ueda; Jin-Young Choi; Diego Aguirre; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2021-01

4.  Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.

Authors:  Xianlun Zou; Yan Luo; John N Morelli; Xuemei Hu; Yaqi Shen; Daoyu Hu
Journal:  Abdom Radiol (NY)       Date:  2021-03-03

Review 5.  Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications.

Authors:  Roberta Catania; Kalina Chupetlovska; Amir A Borhani; Ekta Maheshwari; Alessandro Furlan
Journal:  Abdom Radiol (NY)       Date:  2021-09-14

6.  Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI.

Authors:  Xinai Liu; Xiaoyan Ni; Yubo Li; Chun Yang; Yi Wang; Chunzheng Ma; Changwu Zhou; Xin Lu
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

7.  Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?

Authors:  Sidong Xie; Yao Zhang; Jingbiao Chen; Ting Jiang; Weimin Liu; Dailin Rong; Lin Sun; Linqi Zhang; Bingjun He; Jin Wang
Journal:  Abdom Radiol (NY)       Date:  2021-11-13

8.  Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.

Authors:  Sang Min Lee; Jeong Min Lee; Su Joa Ahn; Hyo Jin Kang; Hyun Kyung Yang; Jeong Hee Yoon
Journal:  Korean J Radiol       Date:  2021-03-09       Impact factor: 3.500

9.  Diagnostic efficacy of dynamic liver imaging using qualitative diagnostic algorithm versus LI-RADS v2018 lexicon for atypical versus classical HCC lesions: A decade of experience from a tertiary liver institute.

Authors:  Shalini Thapar Laroia; Komal Yadav; Archana Rastogi; Guresh Kumar; Senthil Kumar; Shiv Kumar Sarin
Journal:  Eur J Radiol Open       Date:  2020-02-12

10.  Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Diagnostic performance of category-adjusted LR-5 using modified criteria.

Authors:  Jae Hyon Park; Yong Eun Chung; Nieun Seo; Jin-Young Choi; Mi-Suk Park; Myeong-Jin Kim
Journal:  PLoS One       Date:  2020-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.